It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65
Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Rajdeep is an accomplished business leader with a strong techno-commercial background in the healthcare and diagnostic sector
The approval introduces a needle-free alternative to injectable GLP-1 therapies
India’s pharmaceutical sector stands at a pivotal inflection point
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
The company previously completed a $150 million venture investment, acquisition, and recapitalization
Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries
Subscribe To Our Newsletter & Stay Updated
